genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2024
Beam Therapeutics
Genome Editing
CRISPR 2.0: Kinder, Gentler, More Powerful Gene Editing
A-Lists
Top 10 Publicly Owned Gene Editing Therapy Companies
Drug Discovery
StockWatch: Investors Less Forgiving than Analysts as Verve Tumbles
Genome Editing
FDA Approves the First CRISPR Therapy for Sickle Cell Disease
Genome Editing
The First CRISPR Drug: Vertex Pharmaceuticals’ Casgevy Wins U.K. Approval for Sickle Cell Disease
Drug Discovery
Frequency Change: Korro Bio Edits Its Message, Rewrites Its Future with Reverse Merger
Close to the Edge
Beaming Up: CEO John Evans on the Future of Base Editing
GEN Live
A CRISPR Approach to Genetic Medicine
Genome Editing
Base Editing: Putting Precision into Genomic Medicine
Scroll Up
Scroll Up
